Presentation by Dr Emma Wilmot, Derby​, DTN-UK Chair

Part of the DTN-UK Flash Glucose Monitoring Education Programme

In this double-blind, randomized trial, 'abstract of published paper' assigned patients with type 2 diabetes and

albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor,

at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular

filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area

This next deadline of 21st May for data submission to the ABCD nationwide FreeStyle Libre audit has been set for two reasons.  An updated analysis will be undertaken to form the data that will be presented at the  American Diabetes Association annual professional conference between June 7-11, 2019.  This analysis will then be used to write the first paper to be published from the audit.  Data collection will continue beyond this date though 21^st May is an important milestone.

We are all passionate about Technology for Type 1. Taking tech forward depends on getting a comprehensive picture of Type 1 care. If every specialist Type 1 service takes part in the 2018-19 NDA (not just the pump sub-section) it can be done this year. But there are just 2 months to submit 2018-19 data. First reports expected in November. Every service can do it. Please look at the attachments below and if needs be contact your Trust for support.

New data from the Diabetes Foot Care Profiles, published by PHE’s National Cardiovascular Intelligence Network reveals overall number of lower limb amputations continues to rise increasing with white males having the highest.  7,545 major amputations between 2015 and 2018 compared with 6,957 between 2012 to 2015.  The overall number of major amputations is increasing, as the number of people diagnosed with diabetes rises, but the rate among people with diabetes is not significantly increasing.

Here is the opportunity to become a regional advisor for the RCP and get a unique insight into your local area.

The post is unremunerated, which may deter some, however it can be counted as CPD and brings other intangible benefits such seeing job descriptions from other Trust and ensuring that potential consultant colleagues are supported in their roles.

It also gives the opportunity to canvas your local colleague to complete the annual work force survey that provides vital data to help champion our speciality.

In the talk from Dr Fraser Gibb "Reviewing my data: what does it all mean?" the LibreView instructions.

Today at Diabetes UK, ABCD is pleased to announce the full launch of the nationwide semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists that we have to date, and it is now of interest for us to find out to what extent the experience in clinical trials translates into the real world.